Edition:
United Kingdom

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

288.70DKK
16 Nov 2018
Change (% chg)

kr.4.20 (+1.48%)
Prev Close
kr.284.50
Open
kr.287.65
Day's High
kr.290.85
Day's Low
kr.284.35
Volume
1,896,739
Avg. Vol
2,292,503
52-wk High
kr.354.80
52-wk Low
kr.265.15

Select another date:

Thu, Nov 1 2018

Photo

Upbeat sales lift Novo Nordisk as drugmaker weathers U.S. pricing pressure

COPENHAGEN Novo Nordisk , the world's top maker of diabetes drugs, reported encouraging sales of its main growth drivers on Thursday as it announced more job cuts amid a restructuring to cope with intensifying pricing pressure in the United States.

Upbeat sales lift Novo Nordisk as drugmaker weathers U.S. pricing pressure

COPENHAGEN Novo Nordisk , the world's top maker of diabetes drugs, reported encouraging sales of its main growth drivers on Thursday as it announced more job cuts amid a restructuring to cope with intensifying pricing pressure in the United States.

UPDATE 2-Upbeat sales lift Novo Nordisk as drugmaker weathers U.S. pricing pressure

* Expands share buyback programme (Adds CEO comment, details, background)

Novo Nordisk Q3 profit slightly below forecast, nudges up 2018 sales outlook

COPENHAGEN, Nov 1 Denmark's Novo Nordisk , the world's top maker of diabetes drugs, posted third-quarter operating profit slightly below forecasts on Thursday, but lifted the lower end of its sales forecast for the year.

Novo Nordisk hires AstraZeneca executive to revive struggling biopharma unit

COPENHAGEN Novo Nordisk is in advanced talks to acquire assets to bolster its struggling biopharma business, its chief executive said on Monday after the drugmaker announced it had hired an AstraZeneca executive to head the unit.

UPDATE 1-Novo Nordisk hires AstraZeneca executive to revive struggling biopharma unit

COPENHAGEN, Oct 15 Novo Nordisk is in advanced talks to acquire assets to bolster its struggling biopharma business, its chief executive said on Monday after the drugmaker announced it had hired an AstraZeneca executive to head the unit.

Novo Nordisk could close biopharma acquisition this year -CEO

COPENHAGEN, Oct 15 Novo Nordisk might be able to complete an acquisition within its struggling biopharma business this year, its chief executive told Reuters on Monday.

Novo Nordisk picks AstraZeneca executive to head biopharma business

COPENHAGEN, Oct 15 Novo Nordisk has hired AstraZeneca's head of cardiovascular and metabolic diseases to head its biopharma business, which has been struggling with declining sales and a failed acquisition.

Lilly's diabetes drug data impresses, hurts rival Novo's shares

Eli Lilly and Co said on Thursday its new two-in-one diabetes drug was successful in lowering blood sugar and reducing weight, sending its shares to a record high and weighing on those of arch-rival Novo Nordisk .

UPDATE 2-Lilly's diabetes drug data impresses, hurts rival Novo's shares

Oct 4 Eli Lilly and Co said on Thursday its new two-in-one diabetes drug was successful in lowering blood sugar and reducing weight, sending its shares to a record high and weighing on those of arch-rival Novo Nordisk .

Select another date: